Very Early Thrombosis of Sapien 3 Valve.

A 74-year-old man at moderate risk for surgical aortic valve replacement underwent transcatheter aortic valve replacement (TAVR) with an Edwards S3 valve (Edwards Lifesciences, Irvine, California) via the transfemoral route. Past medical history was significant for coronary artery bypass graft surgery. Left ventricular ejection function was normal, and he was in sinus rhythm. A 26-mm valve was successfully deployed without postdilation. Procedure time was 40 min, and activated clotting time during the procedure was 411 s. Dual antiplatelet treatment with aspirin and clopidogrel continued periprocedurally without interruption. Immediate clinical and echocardiographic results were excellent with an aortic valve mean gradient